… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced that it has …
… two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets … collaboration are not disclosed. ProQR is developing its RNA platform technology in areas of ophthalmology, cystic … look forward to collaborating with ProQR and its exciting RNAediting technologies.” About ProQR ProQR Therapeutics is …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced the pricing …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the …
… Operating and Financial Results Development of Axiomer ® RNA base editing technology platform continues across multiple … will focus exclusively on the development of its Axiomer RNAediting technology platform across multiple therapeutic …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the closing …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced that Daniel …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … and ProQR’s RNA oligonucleotide platform and Axiomer RNAediting approaches. Event Details Date/Time: June 22, …